Jules P.P. Meijerink
Boston Children's Hospital
67 Papers
335 Citations
Jules P.P. Meijerink is an academic researcher from Boston Children's Hospital. The author has contributed to research in topics: Leukemia & T cell. The author has an hindex of 32, co-authored 67 publications. Previous affiliations of Jules P.P. Meijerink include Erasmus University Rotterdam & Erasmus University Medical Center.
Chat about Author
Papers
Muc2-deficient mice spontaneously develop colitis, indicating that MUC2 is critical for colonic protection
Maria van der Sluis,Barbara A. E. de Koning,Adrianus C. J. M. de Bruijn,Anna Velcich,Jules P.P. Meijerink,Johannes B. van Goudoever,Hans A. Büller,Jan Dekker,Isabelle Van Seuningen,Ingrid B. Renes,Alexandra W. C. Einerhand +10 more
TL;DR: This study shows that Muc2 deficiency leads to inflammation of the colon and contributes to the onset and perpetuation of experimental colitis.
1.6K
γ-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia
Pedro J. Real,Valeria Tosello,Teresa Palomero,Teresa Palomero,Mireia Castillo,Eva Hernando,Elisa de Stanchina,Maria Luisa Sulis,Maria Luisa Sulis,Kelly Barnes,Catherine M. Sawai,Irene Homminga,Jules P.P. Meijerink,Iannis Aifantis,Giuseppe Basso,Carlos Cordon-Cardo,Weiyun Z. Ai,Adolfo A. Ferrando,Adolfo A. Ferrando +18 more
TL;DR: It is shown that combination therapy with GSIs plus glucocorticoids can improve the antileukemic effects of GSIs and reduce their gut toxicity in vivo and support a role for glucocORTicoid-resistant T-ALL.
Integrated Transcript and Genome Analyses Reveal NKX2-1 and MEF2C as Potential Oncogenes in T Cell Acute Lymphoblastic Leukemia
Irene Homminga,Rob Pieters,Anton W. Langerak,Johan J. de Rooi,Andrew P. Stubbs,Monique Verstegen,Maartje Vuerhard,Jessica Buijs-Gladdines,Clarissa Kooi,Petra Klous,Petra Klous,Pieter Van Vlierberghe,Adolfo A. Ferrando,Jean Michel Cayuela,Brenda Verhaaf,H. Berna Beverloo,Martin A. Horstmann,Valerie de Haas,Anna-Sophia Wiekmeijer,Karin Pike-Overzet,Frank J. T. Staal,Wouter de Laat,Wouter de Laat,Jean Soulier,François Sigaux,Jules P.P. Meijerink +25 more
TL;DR: NKX2-1, NKX22-2, and MEF2C are proposed as T-ALL oncogenes that are activated by various rearrangements.
378
Direct reversal of glucocorticoid resistance by AKT inhibition in acute lymphoblastic leukemia
Erich Piovan,Erich Piovan,Jiyang Yu,Valeria Tosello,Daniel Herranz,Alberto Ambesi-Impiombato,Ana Carolina Da Silva,Marta Sanchez-Martin,Arianne Perez-Garcia,Isaura Rigo,Mireia Castillo,Stefano Indraccolo,Justin R. Cross,Elisa de Stanchina,Elisabeth Paietta,Elisabeth Paietta,Janis Racevskis,Janis Racevskis,Jacob M. Rowe,Martin S. Tallman,Giuseppe Basso,Jules P.P. Meijerink,Carlos Cordon-Cardo,Andrea Califano,Adolfo A. Ferrando +24 more
TL;DR: It is demonstrated that loss of PTEN and consequent AKT1 activation can effectively block glucocorticoid-induced apoptosis and induce resistance to glucoc Corticoid therapy, and pharmacologic inhibition of AKT with MK2206 effectively reverses glucocORTicoid resistance.
267
The human equilibrative nucleoside transporter 1 mediates in vitro cytarabine sensitivity in childhood acute myeloid leukaemia
Isabelle Hubeek,Ronald W. Stam,G.J. Peters,Richard Broekhuizen,Jules P.P. Meijerink,E. R. Van Wering,Brenda Gibson,U Creutzig,Christian M. Zwaan,Jacqueline Cloos,Dirk J. Kuik,Rob Pieters,Gertjan J.L. Kaspers +12 more
TL;DR: In this article, the authors determined mRNA expression of these factors using quantitative-real-time-PCR in leukemic blasts from children diagnosed with acute myeloid leukaemia (AML).